title: Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis.
abstract: We first report a case of patient with refractory dermatomyositis (DM) who successfully treated with tumor necrosis factor-alpha blocker, etanercept and developed necrotizing fasciitis (NF) after the use of it. NF was diagnosed early by MRI and managed with antimicrobial therapy and timely debridement of necrotic tissue with favorable outcome. We suggest that etanercept can be a useful therapeutic agent in patients with DM refractory to steroid and immunosuppressive agents and NF may occur in DM in association with etanercept therapy. We also suggest that management strategies for early diagnosis and treatment are needed for this complication.
authors.affiliation: Department of Internal Medicine, Chonbuk National University Medical School, Chonju, South Korea.
authors.forename: Kyoung-Hwa
authors.initials: KH
authors.lastname: Choi
authors.forename: Wan-Hee
authors.initials: WH
authors.lastname: Yoo
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003646:Debridement; D003882:Dermatomyositis / Q000628:therapy*; D000068800:Etanercept; D019115:Fasciitis, Necrotizing / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D011859:Radiography; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept
references.citation: Arthritis Rheum. 2000 Oct;43(10):2368-77
references.pmid: 11037898
references.citation: N Engl J Med. 1999 Jan 28;340(4):253-9
references.pmid: 9920948
references.citation: Rheumatology (Oxford). 2002 Jul;41(7):828-9
references.pmid: 12096238
references.citation: J Neurol Sci. 1997 Feb 27;146(1):45-51
references.pmid: 9077495
references.citation: Rheumatology (Oxford). 2002 Jan;41(1):22-6
references.pmid: 11792875
references.citation: Eur Neurol. 2004;52(1):61-3
references.pmid: 15240986
references.citation: Arthritis Rheum. 2005 Sep;52(9):2607-15
references.pmid: 16142757
references.citation: Postgrad Med J. 2002 Jan;78(915):47-8
references.pmid: 11796874
references.citation: Lancet. 2000 Jan 1;355(9197):53-7
references.pmid: 10615903
references.citation: N Engl J Med. 2000 Nov 30;343(22):1586-93
references.pmid: 11096165
references.citation: Rheum Dis Clin North Am. 2002 Nov;28(4):799-822
references.pmid: 12506773
references.citation: Ann Rheum Dis. 2002 Sep;61(9):848-9
references.pmid: 12176816
references.citation: Ann Rheum Dis. 2006 Sep;65(9):1233-6
references.pmid: 16476710
references.citation: Aust N Z J Med. 1997 Feb;27(1):29-34
references.pmid: 9079250
references.citation: Eur Neurol. 2003;50(1):10-5
references.pmid: 12824706
references.citation: Rheumatology (Oxford). 2004 Apr;43(4):524-6
references.pmid: 15024139
references.citation: Arthritis Rheum. 2005 Apr 15;53(2):155-65
references.pmid: 15818648
references.citation: Medicine (Baltimore). 2004 Jan;83(1):35-42
references.pmid: 14747766